质子泵抑制剂与其他药物相互作用的药学监护实践

中国药物警戒 ›› 2016, Vol. 13 ›› Issue (7): 429-432.

• 安全性评价与合理用药 • 上一篇下一篇

质子泵抑制剂与其他药物相互作用的药学监护实践

李海燕, 胡斌

西安市第四医院药剂科，陕西西安 710004

收稿日期:2016-03-01 修回日期:2018-07-17 出版日期:2016-07-20 发布日期:2018-07-17
作者简介:李海燕，女，硕士，主管药师，临床药学。

Pharmaceutical Care Practice of Proton Pump Inhibitors and Its Interactions with Other Drugs

LI Hai-yan, HU Bin

Department of Pharmacy, Xi’an No.4 Hospital, Shaanxi Xi’an 710004, China

Received:2016-03-01 Revised:2018-07-17 Online:2016-07-20 Published:2018-07-17

摘要/Abstract

摘要： 目的为临床药师开展基于药物相互作用的药学监护提供参考。方法结合临床药师在临床实践中监护的质子泵抑制剂（PPIs）与其他药物的相互作用实例，探讨如何开展以药物相互作用为切入点的临床药学服务，以避免药物相互作用引起的药效降低及不良反应的发生。结果与结论临床药师必须深入临床，提高职业敏感性，及时发现潜在的药物相互作用并给予干预，发挥临床药师所具备的药学专业优势，保证患者用药安全。

关键词: 临床药师, 药物相互作用, 质子泵抑制剂

Abstract: Objective To provide reference for clinical pharmacists to carry out drug-drug interactions based medication monitoring. Methods In clinical practice, clinical pharmacists often encounter drug-drug interaction instances of proton pump inhibitors (PPIs) with other drugs, the investigation in how to carry out clinical pharmacy care considering of medicine interactions as the main point helps to avoid reduced potency and adverse drug reactions due to medicine interactions. Results & Conclusion Only through participating in the clinical work, discovering potential drug-drug interactions and giving interventions on time, patient’s medication can be ensured safely. The clinical pharmacists must improve occupational sensitivity and find the right way to make full use of expertise and advantage.

Key words: clinical pharmacist, drug interaction, proton pump inhibitors

中图分类号:

R969.2

李海燕, 胡斌. 质子泵抑制剂与其他药物相互作用的药学监护实践[J]. 中国药物警戒, 2016, 13(7): 429-432.

LI Hai-yan, HU Bin . Pharmaceutical Care Practice of Proton Pump Inhibitors and Its Interactions with Other Drugs [J]. Chinese Journal of Pharmacovigilance, 2016, 13(7): 429-432.

参考文献

[1] 中国医院协会药事管理专业委员会.质子泵抑制剂临床应用的药学监护[M].1版，人民卫生出版社，2013 : 6，27-29.
[2] Ishizaki T,Horai Y. Review article：cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole [J]. Alimentary Pharmacology&Therapeutics,1999, 13 (S3) : 27-36.
[3] Lind T, Rydberg L, Kyleback A. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastrooesophageal reflux disease[J]. Alimentary Pharmacology & Therapeutics,2000, 14(7) : 861-867.
[4] Blume H, Donath F, Warnke A, et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors[J]. Drug Safety, 2006, 29(9) : 769-784.
[5] 刘波, 姚鸿萍. 临床常用质子泵抑制剂的研究进展[J].西北药学杂志, 2014, 29(3) : 328-332.
[6] 周尔文, 寿军, 李光武, 等.综合性医院门诊处方中常见CYP3A4抑制剂和诱导剂的代谢性相互作用调查[J].中国医药指南, 2013, 11(19) : 489-491.
[7] 祝锡聪. 埃索美拉唑的临床应用与安全性[J].药物流行病学杂志, 2007, 16(4) : 215-217.
[8] 李旭梅,涂厉标.奥美拉唑的化学配伍禁忌及药物相互作用[J].中国临床药学杂志,2009, 18(5) : 320-322.
[9] 陈坚. 质子泵抑制剂的分类及药理学特性[J]. 上海医药, 2013, 34(21) : 3-7.
[10] 彭华, 程泽能. 细胞色素P450-3A4相关的药物相互作用[J]. 中国临床药理学杂志, 2001, 17(5) : 379-385.
[11] David W J, Clark, Johanna Strandell. Myopathy including polymyositis:a likely class adverse effect of proton pump inhibitors[J].European Journal of Clinical Pharmacology, 2006, 62(6) : 473-479.
[12] Vlase L,Neag M, Popa A, et al.Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers:a prospective pilot study[J]. Current Therapeutic Research, 2010,71(6) : 360-368.
[13] F.Itagaki, M.Homma, K.Yuzawa,et al. Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation[J]. Transplantation Proceedings, 2002, 34(7) : 2777-2778.
[14] Calabresi L, Pazzucconi F, Ferrara S, et al. Pharmacokinetic interaction between omeprazole/pantoprazole and clarithromycin in healthy volunteers[J]. Pharmacological Reasearch, 2004, 49(5) :493-499.
[15] Pilsgaard H D, Bjerregaard S T,Rix H M , et al. The potential drug-drug interaction between proton pump inhibitors and warfarin[J]. Pharmacoepidemiology & Drug Safety, 2015, 24 : 1337–1340.
[16] Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy[J]. European Heart Journal, 2013, 34 : 1708–1713.
[17] Gilard M, Arnaud B, Cornily J C, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study[J]. Journal of the American College of Cardiology, 2008, 51(3) : 256-260.
[18] Zuern C S,Geisler T,Lutilsky N, et al. Effect of comedication with proton pump inhibitors(PPI) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy[J]. Thrombosis Research, 2010, 125 : e51-e54.
[19] Troger U，Stotzel B，Martens-Lobenhoffer J, et al. Severe myalgia from an interaction between treatments with pantoprazole and
methotrexate[J]. British Medical Journal, 2002, 324(7352) : 1 497.
[20] Yucel E, Sancar M,Yucel A. Adverse drug reactions due to drug- drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method[J]. Expert Opinion on Drug Safety, 2016, 15(2) : 223-236.
[21] Bouziana S D, Tziomalos K. Clinical relevance of clopidogrel-proton pump inhibitors interaction[J]. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2015, 6(2) : 17-21.
[22] 魏春燕, 吴逢波. CYP450与药物相互作用[J].中国药业, 2014, 23(6) : 17-20.

质子泵抑制剂与其他药物相互作用的药学监护实践

Pharmaceutical Care Practice of Proton Pump Inhibitors and Its Interactions with Other Drugs

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	范凯凯, 王聪, 刘洪峰, 王西勇. 临床药师对某院丙氨酰谷氨酰胺注射液应用干预分析[J]. 中国药物警戒, 2024, 21(2): 181-184.
[2]	黎杏仁, 沈爱宗, 苏丹. 质子泵抑制剂预防胆胰外科围术期应激性黏膜病变的合理性评价[J]. 中国药物警戒, 2023, 20(9): 1022-1026.
[3]	陈婕, 秦侃. 肠外营养个体化给药实践评价[J]. 中国药物警戒, 2023, 20(7): 812-816.
[4]	刘婧, 夏亮, 张世杰. 1例多元药物过敏急性胰腺炎患者行药物激发试验的药学监护[J]. 中国药物警戒, 2023, 20(7): 822-824.
[5]	苏甦, 伍诗琪, 张青霞, 闫素英. 1例吲达帕胺致粒细胞缺乏症患者的药学监护[J]. 中国药物警戒, 2023, 20(11): 1282-1285.
[6]	张雯雯, 聂西庭, 徐会茹, 冉晔, 田成林, 于生元. 华法林片联合复方氨酚烷胺片致凝血功能极度异常1例分析[J]. 中国药物警戒, 2023, 20(11): 1290-1292.
[7]	谢婧, 关飞. 药物诱发髂腰臀肌自发性出血1例分析[J]. 中国药物警戒, 2023, 20(11): 1299-1302.
[8]	赵瑞, 于晓佳, 安卓玲. 1例大剂量胺碘酮诱发伊伐布雷定闪光现象的药学监护[J]. 中国药物警戒, 2023, 20(10): 1173-1175.
[9]	卫红涛, 沈素, 李丹丹, 廖音. 705例神经内科问题医嘱的帕累托图分析[J]. 中国药物警戒, 2022, 19(8): 900-903.
[10]	原小陇, 万齐华, 陶东红, 祁浩, 王爱霞. 1例甲氨蝶呤片严重中毒患者的药学监护[J]. 中国药物警戒, 2022, 19(8): 924-928.
[11]	孙雪林, 张攀, 胡欣. 1例维得利珠单抗治疗重症溃疡性结肠炎的药学监护[J]. 中国药物警戒, 2022, 19(7): 782-785.
[12]	唐静雅. 临床药师参与1例肠外营养相关性肝损伤治疗的药学监护[J]. 中国药物警戒, 2022, 19(7): 786-788.
[13]	杨宝春, 孙欣, 杨欣, 吴琳, 王丽萍. 临床药师参与1例尿路感染伴药物热患者药学实践[J]. 中国药物警戒, 2022, 19(5): 572-573.
[14]	陈方方, 张红旭. 大剂量甲氨蝶呤治疗原发性中枢神经系统淋巴瘤的药学实践[J]. 中国药物警戒, 2022, 19(4): 446-449.
[15]	李友佳, 谢姣, 姚红伊, 计成. 1例甲状旁腺功能减退性心肌病患者的药学监护[J]. 中国药物警戒, 2022, 19(11): 1254-1257.